Epstein-Barr Virus Infection after Unrelated Cord Blood Transplantation: Reactivation or Reinfection?

  • Keisei Kawa
  • Akihisa Sawada
  • Maho Koyama
  • Masami Inoue
Letter to the Editor

References

  1. 1.
    Kawabata Y, Hirokawa M, Saitoh Y, et al. Late-onset fatal Epstein-Barr virus-associated hemophagocytic syndrome following cord blood cell transplantation for adult acute lymphoblastic leukemia.Int J Hematol. 2006;84:445–448.PubMedCrossRefGoogle Scholar
  2. 2.
    Kawa K . Hemophagocytic syndrome-treatment strategies according to classification and scoring system. In:Education Program Book of the 67th Annual Meeting of the Japanese Society of Hematology and the 47th Annual Meeting of the Japanese Society of Clinical Hematology. Tokyo, Japan; 2005:72–75.Google Scholar
  3. 3.
    Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.Blood. 1998;92:1549- 1555.PubMedGoogle Scholar
  4. 4.
    Ohga S, Kanaya Y, Maki H, et al. Epstein-Barr virus-associated lymphoproliferative disease after a cord blood transplant for Diamond-Blackfan anemia.Bone Marrow Transplant. 2000;25:209–212.PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen J, Gandhi M, Naik P, et al. Increased incident of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning.Br J Haematol. 2005;129:229–239.PubMedCrossRefGoogle Scholar
  6. 6.
    Agbalika F, Larghero J, Esperou H, et al. Epstein-Barr virus early-antigen antibodies before allogeneic haematopoietic stem cell transplantation as a marker of risk of post-transplant lymphoproliferative disorders.Br J Haematol. 2006;136:305–308.CrossRefGoogle Scholar
  7. 7.
    Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated cord blood transplantation.Blood. 2006;108:2874–2880.PubMedCrossRefGoogle Scholar
  8. 8.
    Gratama JW, Oosterveer MAP, Zwaan FE, et al. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implication for sites of viral latency.Proc Natl Acad Sci USA. 1988;85:8693–8696.PubMedCrossRefGoogle Scholar
  9. 9.
    Qu L, Xu S, Rowe D, Triulzi D. Efficacy of Epstein-Barr virus removed by leukoreduction of red blood cells.Transfusion. 2005;45:591–595.PubMedCrossRefGoogle Scholar
  10. 10.
    Meijer E, Spijkers S, Moschatsis S, et al. Active Epstein-Barr virus infection after allogeneic stem cell transplantation: re-infection or reactivation?Transpl Infect Dis. 2005;7:4–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Yagita M, Iwakura H, Kishimoto T, et al. Successful allogeneic stem cell transplantation from an unrelated donor for aggressive Epstein-Barr virus-associated clonal T-cell proliferation with hemophagocytosis.Int J Hematol. 2001;74:451–454.PubMedCrossRefGoogle Scholar
  12. 12.
    Gratama JW, Lennette ET, Lonnqvist B, et al. Detection of multiple Epstein-Barr viral strains in allogeneic bone marrow transplant recipients.J Med Virol. 1992;37:39–47.PubMedCrossRefGoogle Scholar
  13. 13.
    Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.Crit Rev Oncol Hematol. 2002;44:259–272.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2007

Authors and Affiliations

  • Keisei Kawa
    • 1
  • Akihisa Sawada
    • 1
  • Maho Koyama
    • 1
  • Masami Inoue
    • 1
  1. 1.Division of Hematology/OncologyOsaka Medical Center and Research Institute for Maternal and Child HealthIzumi, OsakaJapan

Personalised recommendations